Yordas Group

View Original

Withdrawal of support for the active substance Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5 (1H,3H)-dione (TMAD) from the BPR Review Programme

Rebecca Trulock

The following active substance/product-type combination is no longer considered to be supported in the Biocidal Products Regulation (BPR) Review Programme:

  1. Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5 (1H,3H)-dione (TMAD)

    Product type 12 (slimicides)